Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomericaBMRA -6.28%50 Forward Dividend Yield % is 0.00% as of Aug. 01, 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 311 Medical Devices & Instruments companies, Biomerica ranks worse than 321543.09% on this metric.
As of today (2026-08-01), the Forward Annual Dividend Yield of Biomerica is 0.00%.
As of today (2026-08-01), the Trailing Annual Dividend Yield of Biomerica is 0.00%.
BMRA's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.12 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
BMRA vs WOK, ALURD, ITOC: Forward Dividend Yield % Comparison
For the Medical Devices subindustry, Biomerica's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomerica Forward Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Biomerica's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Biomerica (BMRA) has a Forward Dividend Yield % of 0.00% as of Aug. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biomerica and its competitors. According to the industry distribution chart, Biomerica ranks #999999 out of 311 companies in the Medical Devices & Instruments industry.
Is Biomerica's Forward Dividend Yield % too high?
Biomerica's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Biomerica ranks #999999 out of 311 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Forward Dividend Yield % compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #999999 out of 311 companies for Forward Dividend Yield %. This places Biomerica in the lower half of its industry. The industry median Forward Dividend Yield % is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.12, based on 311 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biomerica and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomerica's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Biomerica (BMRA), the current Forward Dividend Yield % is 0.00% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomerica (BMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Biomerica stock appears to be undervalued.
The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18.
GuruFocus considers Biomerica to be Possible Value Trap.
Key valuation signals for BMRA:
Forward Dividend Yield %: 0.00%
GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score
Get the complete analysis for BMRA
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRA has been successfully added to your 
